Schrödinger, Inc. Board of Directors

Schrödinger, Inc., together with its subsidiaries, develops physics-based computational platform that enables discovery of novel molecules for drug development and materials applications. The company operates in two segments, Software and Drug Discovery. The Software segment is focused on licensing its software to transform molecular discovery for life sciences and materials science industries. The Drug Discovery segment focuses on building a portfolio of preclinical and clinical programs, internally and through collaborations. The company serves biopharmaceutical and industrial companies, academic institutions, and government laboratories worldwide. It has a research collaboration and license agreement with Novartis AG to advance multiple development candidates. Schrödinger, Inc. was incorporated in 1990 and is based in New York, New York.

Dr. Ramy Farid Ph.D.

Dr. Ramy Farid Ph.D.

CEO, President & Director

Mr. Kenneth Patrick Lorton

Mr. Kenneth Patrick Lorton

Executive VP, CTO & COO of Software

Ms. Jaren Irene Madden

Ms. Jaren Irene Madden

Senior Vice President of Investor Relations & Corporate Affairs

Mr. Shane Brauner

Mr. Shane Brauner

Executive VP & Chief Information Officer

Dr. Robert Lorne Abel Ph.D.

Dr. Robert Lorne Abel Ph.D.

Executive VP, Chief Scientific Officer of Platform and Head of Modeling R&D

Dr. Karen Akinsanya Ph.D.

Dr. Karen Akinsanya Ph.D.

President of Research & Development Therapeutics

Prof. William Goddard III

Prof. William Goddard III

Co-Founder & Scientific Advisor

Dr. Richard A. Friesner Ph.D.

Dr. Richard A. Friesner Ph.D.

Co-Founder, Scientific Advisory Chairman and Director

Leaving Board of Directors Review Your about to visit the following url Invalid URL

Loading...
Comments


Comment created.